Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-011555
Filing Date
2021-08-13
Accepted
2021-08-13 06:07:25
Documents
105
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q jagx-20210630x10q.htm   iXBRL 10-Q 3429034
2 EX-31.1 jagx-20210630xex31d1.htm EX-31.1 11018
3 EX-31.2 jagx-20210630xex31d2.htm EX-31.2 11017
4 EX-32.1 jagx-20210630xex32d1.htm EX-32.1 6964
5 EX-32.2 jagx-20210630xex32d2.htm EX-32.2 6939
  Complete submission text file 0001558370-21-011555.txt   14892588

Data Files

Seq Description Document Type Size
6 EX-101.SCH jagx-20210630.xsd EX-101.SCH 132870
7 EX-101.CAL jagx-20210630_cal.xml EX-101.CAL 78365
8 EX-101.DEF jagx-20210630_def.xml EX-101.DEF 639636
9 EX-101.LAB jagx-20210630_lab.xml EX-101.LAB 942834
10 EX-101.PRE jagx-20210630_pre.xml EX-101.PRE 882674
11 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20210630x10q_htm.xml XML 2341692
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36714 | Film No.: 211169599
SIC: 2834 Pharmaceutical Preparations